AKRX - エイコ―ン (Akorn Inc.) エイコ―ン



symbol AKRx
会社名 Akorn Inc (エイコ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アコルン(Akorn Inc.)は一連の診断用・治療用眼科医薬品、病院薬剤及び注射用医薬品を製造・販売する企業である。同社は眼科事業、病院薬・注射剤事業、及び契約サービス事業という3つの事業部門を運営する。同社は米国イリノイ州のディケーターとニュージャージー州のサマセット、及びインドのヒマーチャルプラデーシュ州Paonta Sahibにある薬品製造プラント、イリノイ州のガーニにある中央物流倉庫、イリノイ州のスコーキーとヴァーノンヒルズにある研究・開発(R&D)センター、及びイリノイ州のレークフォレストにある企業オフィスを運営する。同社の顧客は医師、眼科、病院、卸売業者、共同購入団体、小売薬局チェーンや他の製薬会社を含む。平成24年2月28日、同社は完全子会社Akorn India Private Limitedを通して、Kilitch Drugs (India) Limitedの一部の資産、及びNBZ Pharma Limitedの一部の資産を取得した。   エイコ―ンは米国の製薬会社。眼科の診断・治療薬のほか、病院の薬や注射用医薬品を開発、製造、販売する。ドライアイの治療に「テ―ラティア―ズ」のブランド名で眼科医薬品を製造、店頭で販売する。主要な販売製品には、眼科、解毒剤、抗感染、ワクチンのほか、疼痛管理や麻酔のための規制物質など様々な分野での診断・治療医薬品がある。   Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health business segments. The Prescription Pharmaceuticals segment manufactures and markets generic and branded prescription pharmaceuticals including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The Consumer Health segment offers branded and private-label animal health; and over-the-counter products. The company was founded in 1971 and is headquartered in Lake Forest, IL.
本社所在地 1925 W. Field Court Suite 300 Lake Forest IL 60045 USA
代表者氏名 Alan D. Weinstein アラン・D・ワインスタイン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 847-279-6100
設立年月日 25934
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 2308人
url www.akorn.com
nasdaq_url https://www.nasdaq.com/symbol/akrx
EBITDA EBITDA(百万ドル) -48.77200
終値(lastsale) 6.325
時価総額(marketcap) 793478675.55
時価総額 時価総額(百万ドル) 810.41460
売上高 売上高(百万ドル) 763.49200
企業価値(EV) 企業価値(EV)(百万ドル) 1331.4356
当期純利益 当期純利益(百万ドル) -211.74700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akorn Inc. revenues decreased 17% to $375M. Net loss totaled $116.7M vs. income of $43.6M. Revenues reflect Prescription Pharmaceuticals segment decrease of 20% to $336.5M. Net loss reflects Research and development expenses increase from $27.2M to $105.2M (expense) Selling general and administrative expe increase of 44% to $146.7M (expense).



   Drugmaker Akorn files for bankruptcy protection after failed sale  2020/05/21 18:19:05 Reuters
Generic drugmaker Akorn Inc filed for bankruptcy protection late Wednesday, citing the overhang of litigation stemming from German healthcare company Fresenius SE's decision two years ago to terminate an over $4 billion acquisition of the company.
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.
   Global Medical Cannabis Market Insights 2020, Featuring Insys Therapeutics, Alkem Laboratories, Akorn and Ascent Pharmaceuticals - ResearchAndMarkets.com  2020/05/15 12:48:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Medical Cannabis Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering. The "2020 Global and Chinese Medical Cannabis" report provides key statistics on the market for medical cannabis. It is a valuable source of guidance and direction for companies and individuals interested in Medical Cannabis industry. Key points of Medical Can

 関連キーワード  (医薬品 米国株 エイコ―ン AKRX Akorn Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)